- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00997061
SCOT Registry: Small Cell Lung Cancer Treatment and Outcome (SCOT)
The registry is an international, multicenter, observational registry of newly diagnosed patients with SCLC.
Data will be entered into an electronic CRF (eCRF) via Internet access. Treatment plan remains the responsibility of the patient's physician and data collected in this registry will reflect a "real world" approach of the diagnosis and treatment of patients with SCLC.
Approximately 60 centres in 13 countries will take part in this registry. It is expected that about 500 patients will be recruited during a period of 6 to 9 months according to the feasibility.
Study Overview
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Graz, Austria, A-8036
- GSK Investigational Site
-
Innsbruck, Austria, A-6020
- GSK Investigational Site
-
Salzburg, Austria, 5020
- GSK Investigational Site
-
Vienna, Austria, 1130
- GSK Investigational Site
-
-
-
-
-
Brno, Czech Republic, 625 00
- GSK Investigational Site
-
Plzen, Czech Republic, 305 99
- GSK Investigational Site
-
-
-
-
-
Tallinn, Estonia, 11619
- GSK Investigational Site
-
-
-
-
-
Besançon, France, 25030
- GSK Investigational Site
-
Caen, France, 14033
- GSK Investigational Site
-
Créteil, France, 94010
- GSK Investigational Site
-
Draguignan cedex, France, 83300
- GSK Investigational Site
-
Lorient cedex, France, 56322
- GSK Investigational Site
-
Paris, France, 75020
- GSK Investigational Site
-
Perpignan, France, 66000
- GSK Investigational Site
-
Pessac cedex, France, 33604
- GSK Investigational Site
-
Pierre Benite, France, 69495
- GSK Investigational Site
-
Saint-Priest en Jarez, France, 42271
- GSK Investigational Site
-
Strasbourg, France, 67091
- GSK Investigational Site
-
-
-
-
Bayern
-
Muenchen, Bayern, Germany, 81925
- GSK Investigational Site
-
-
Hessen
-
Immenhausen, Hessen, Germany, 34376
- GSK Investigational Site
-
Kassel, Hessen, Germany, 34125
- GSK Investigational Site
-
Wiesbaden, Hessen, Germany, 65199
- GSK Investigational Site
-
-
Niedersachsen
-
Leer, Niedersachsen, Germany, 26789
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Bonn, Nordrhein-Westfalen, Germany, 53113
- GSK Investigational Site
-
Hemer, Nordrhein-Westfalen, Germany, 58675
- GSK Investigational Site
-
Koeln, Nordrhein-Westfalen, Germany, 51109
- GSK Investigational Site
-
Velbert, Nordrhein-Westfalen, Germany, 42551
- GSK Investigational Site
-
-
-
-
-
Athens, Greece, 115 27
- GSK Investigational Site
-
Heraklion, Crete, Greece, 71110
- GSK Investigational Site
-
Thessaloniki, Greece, 57010
- GSK Investigational Site
-
-
-
-
-
Mátraháza, Hungary, 3233
- GSK Investigational Site
-
Székesfehérvár, Hungary, 8000
- GSK Investigational Site
-
-
-
-
Emilia-Romagna
-
Parma, Emilia-Romagna, Italy, 43100
- GSK Investigational Site
-
-
Lombardia
-
Rozzano (MI), Lombardia, Italy, 20089
- GSK Investigational Site
-
-
Piemonte
-
Orbassano (TO), Piemonte, Italy, 10043
- GSK Investigational Site
-
-
Puglia
-
Lecce, Puglia, Italy, 73100
- GSK Investigational Site
-
-
Sardegna
-
Sassari, Sardegna, Italy, 07100
- GSK Investigational Site
-
-
-
-
-
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707
- GSK Investigational Site
-
Seoul, Korea, Republic of, 137-701
- GSK Investigational Site
-
Suwon, Gyeonggi-do, Korea, Republic of, 442-723
- GSK Investigational Site
-
-
-
-
-
Kaunas, Lithuania, LT-50009
- GSK Investigational Site
-
Klaipeda, Lithuania, LT-92228
- GSK Investigational Site
-
Vilnius, Lithuania, LT-08660
- GSK Investigational Site
-
Vilnius, Lithuania, LT-08661
- GSK Investigational Site
-
-
-
-
-
Amsterdam, Netherlands, 1081 HV
- GSK Investigational Site
-
Breda, Netherlands, 4818 CK
- GSK Investigational Site
-
Eindhoven, Netherlands, 5623 EJ
- GSK Investigational Site
-
Groningen, Netherlands, 9713 GZ
- GSK Investigational Site
-
-
-
-
-
Glucholazy, Poland, 41-340
- GSK Investigational Site
-
Gorzow Wielkopolski, Poland, 66-400
- GSK Investigational Site
-
Krakow, Poland, 31-115
- GSK Investigational Site
-
Lodz, Poland, 93-509
- GSK Investigational Site
-
Lublin, Poland, 20-954
- GSK Investigational Site
-
Warszawa, Poland, 00-909
- GSK Investigational Site
-
-
-
-
-
Golnik, Slovenia, 4204
- GSK Investigational Site
-
Ljubljana, Slovenia, 1000
- GSK Investigational Site
-
-
-
-
-
Cordoba, Spain, 14004
- GSK Investigational Site
-
Madrid, Spain, 28040
- GSK Investigational Site
-
Madrid, Spain, 28034
- GSK Investigational Site
-
Palma de Mallorca, Spain, 07014
- GSK Investigational Site
-
Zaragoza, Spain, 50009
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or Female >/= 18 years
- Diagnosis of small cell lung cancer
- Patient newly diagnosed with SCLC
- Has given written informed consent (if applicable)
Exclusion Criteria:
- Concurrent history of other neoplasm, except curatively treated basal cell skin cancer or adequately treated in-situ carcinoma of the cervix.
- Patient presenting with recurrence of SCLC.
- Patients who has received any chemotherapy for the SCLC.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
HYCAMTIN
|
Observing patients on HYCAMTIN and other drugs for SCLC.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Registry with disease, treatment and outcome data collected.
Time Frame: 6-9mth recruitment period, 18mth study duration.
|
6-9mth recruitment period, 18mth study duration.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
survival rates
Time Frame: 18 month period
|
18 month period
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Topotecan
Other Study ID Numbers
- 112791
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer, Small Cell
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedTobacco Use Disorder | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB...United States
-
Washington University School of MedicineMerck Sharp & Dohme LLCWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Small Cell Lung Extensive Stage
-
Shanghai Chest HospitalRecruitingSmall Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Limited Stage | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer, Combined TypeChina
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
Clinical Trials on HYCAMTIN
-
GlaxoSmithKlineCompletedLung Cancer, Non-Small CellUnited States, Slovakia, Russian Federation, Hungary, Canada, Poland
-
Northwestern UniversityNational Cancer Institute (NCI); GlaxoSmithKlineCompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Recurrent Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Adult Liposarcoma | Metastatic Liposarcoma | Recurrent LiposarcomaUnited States
-
SCRI Development Innovations, LLCGlaxoSmithKlineCompletedSmall Cell Lung Cancer | Carcinoma, Small CellUnited States
-
North Eastern German Society of Gynaecological...Completed
-
BioNumerik Pharmaceuticals, Inc.Crown BioscienceCompletedOvarian CancerPoland, Russian Federation, Romania, Hungary, Lithuania
-
Accelerated Community Oncology Research NetworkGlaxoSmithKlineCompleted
-
Celgene CorporationCompletedSmall Cell Lung CancerUnited States
-
National Cancer Institute (NCI)CompletedGlioblastoma | Brain Neoplasms | Central Nervous System Neoplasms | Glioblastoma Multiforme | GliosarcomaUnited States
-
GlaxoSmithKlineTerminated
-
North Eastern German Society of Gynaecological...Completed